MeSH tree: C12.200.777.419.570.363.680
An already-approved IV drug significantly reduces the symptoms of lupus, a new clinical trial showed. More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms ...
5 hours ago
0
0
Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in disease pathogenesis, according to a study led by Weill Cornell Medicine ...
Nov 24, 2025
0
28
Researchers at the University Hospital Bonn (UKB) and the University of Bonn have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering a chain reaction.
Nov 3, 2025
0
43
In a finding set to change the way disease is monitored, Chandra Mohan, an international expert and pioneer in lupus research at the University of Houston, is reporting that urine samples can indicate lupus nephritis in a ...
Oct 21, 2025
0
0
Cedars-Sinai investigators have identified a "molecular switch" on a gene strongly associated with the autoimmune disease lupus, which appears to propel immune cells into overdrive, attacking and damaging healthy tissues ...
Oct 13, 2025
0
0
In lupus nephritis, attainment of complete renal response (CRR)/partial renal response (PRR) and lupus low disease activity state (LLDAS) is associated with best relapse-free survival, with independent associations seen with ...
Aug 14, 2025
0
0
At the time when patients with lupus, or systemic lupus erythematosus (SLE), are diagnosed, approximately 15% to 30% will already have the inflammation-caused kidney disease lupus nephritis, which compromises kidney function ...
Aug 5, 2025
0
0
The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving standard therapy.
Jul 1, 2025
0
0
For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard therapy is more efficacious for providing a complete renal response than standard therapy alone, according ...
Feb 26, 2025
0
0
A Berlin-led research team has uncovered critical regulators of severe kidney damage in patients with lupus, an autoimmune disorder affecting an estimated five million people worldwide, most of whom are young women. A small, ...
Aug 14, 2024
0
15
